Sort
40,608 grants matching “prostate cancer”
Academic-Industry Partnership for the Translation of a 4D in vivo Dosimetry Approach for Radiation Therapy
$392,615Liangzhong Shawn Xiang · University Of California-Irvine · R37 · FY2023 · CA
Molecular Imaging of Protein Glycosylation in Living Subjects
$392,583Adam De La Zerda · Stanford University · DP5 · FY2016 · OD
Molecular Imaging of Protein Glycosylation in Living Subjects
$392,581Adam De La Zerda · Stanford University · DP5 · FY2015 · OD
Molecular Imaging of Protein Glycosylation in Living Subjects
$392,577Adam De La Zerda · Stanford University · DP5 · FY2014 · OD
Molecular Imaging of Protein Glycosylation in Living Subjects
$392,572Adam De La Zerda · Stanford University · DP5 · FY2012 · OD
Tumor stem cells and metastatic outcomes in mouse models of prostate cancer
$392,536Kathleen Kelly · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
Development of a universal tagging method for genome wide ChIP analyses
$392,500Zhenghe Wang · Case Western Reserve University · R01 · FY2009 · HG
Development of a universal tagging method for genome wide ChIP analyses
$392,500Zhenghe Wang · Case Western Reserve University · R01 · FY2008 · HG
Transcriptional signalling by vitamin A
$392,500Noa Noy · Case Western Reserve University · R01 · FY2010 · DK
Evaluation of novel therapies for vesicant skin toxicities
$392,498Carl W White · University Of Colorado Denver · U54 · FY2012 · ES
Modulators of Prostate Cancer Metastasis
$392,467Children'S Hospital Boston · R37 · FY2001 · CA
VITAMIN D LEVELS AND RELATED GENETIC POLYMORPHISMS, SUN EXPOSURE, SKIN COLOR, AND RISK OF AGGRESSIVE PROSTATE CANCER
$392,431Northwestern University · · FY2010 · Department of the Army
Whole Genome Sequencing to Discover Familial Myeloma Risk Genes
$392,428Steven Monroe Lipkin · Weill Medical Coll Of Cornell Univ · R01 · FY2012 · CA
3D genome architecture and the origins of recurrent genomic rearrangements in prostate cancer
$392,423Ram Shankar Mani · Ut Southwestern Medical Center · R01 · FY2022 · CA
Biostatistics, Analytical Support, and Evaluation Shared Resource (BASE SR)
$392,413Gang Li · University Of California Los Angeles · P30 · FY2025 · CA
PSM Moffitt Cancer Center Partnership
$392,412Jose A Torres-Ruiz · Ponce School Of Medicine · U56 · FY2006 · CA
Understanding the full spectrum of epigenetic vulnerability in cancer through the delineation of DNA methylation function in gene 3' end
$392,412Angela H Ting · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA
SBIR Phase I Topic 402: Artificial Intelligence-Aided Imaging for Cancer Prevention, Diagnosis, and Monitoring
$392,343Xin Qi · Reveal Biosciences, Inc. · N43 · FY2020 · CA
Prostate-Specific Androgen Transporters are the Missing Target for Complete ADT
$392,306Gary J Smith · Roswell Park Cancer Institute Corp · R01 · FY2017 · CA
Prostate Cancer Vulnerabilities to BH3 Mimetic Drugs
$392,306Steven P. Balk · Beth Israel Deaconess Medical Center · R01 · FY2022 · CA
Racial Differences in Prostate Cancer Molecular Subtyping
$392,306Michael R Freeman · Cedars-Sinai Medical Center · R01 · FY2022 · CA
Prostate-Specific Androgen Transporters are the Missing Target for Complete ADT
$392,306Gary J Smith · Roswell Park Cancer Institute Corp · R01 · FY2018 · CA
Prostate-Specific Androgen Transporters are the Missing Target for Complete ADT
$392,306Gary J Smith · Roswell Park Cancer Institute Corp · R01 · FY2016 · CA
Prostate Cancer Vulnerabilities to BH3 Mimetic Drugs
$392,306Steven P. Balk · Beth Israel Deaconess Medical Center · R01 · FY2023 · CA
Prostate-Specific Androgen Transporters are the Missing Target for Complete ADT
$392,306Gary J Smith · Roswell Park Cancer Institute Corp · R01 · FY2020 · CA